Cabot Corporation (CBT) 12-Month Stock Forecast & Price Target Cone

$73.85 +0.11% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $74.04

Cabot Corporation (CBT) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (25% profit margin, 22% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $3.81B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $74.04 (+0.26%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 10.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510077
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+
Cash (16)Whales (11)SEC (15)Macro (17)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE+8.5% Base Target
$99 Bull$80 Base$61 Bear
📬 FREE CBT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CBT)Realized 20D OHLCV Swing Band: ±4.5%
Deterministic 5-Pillar Attribution (77/100 Composite)
🔍 WHY CBT SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Macro Regime Fit+17/20 pts (22% of score)

FRED Regime × Technicals: 43% of 52W Range • RSI-14 at 43.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
85
Grade A$74.91-0.8% Next Q
Q2 (-2Q)
82
Grade A$74.29-0.7% Next Q
Q3 (-1Q)
80
Grade A-$73.79+0.1% Next Q
Current
77
Grade B+$73.85+7.8% Hist 90D α
Trajectory: A (85) → B+ (77)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CBT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, CBT faces multiple-compression risk if 11.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 22.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($77.95) or 200D SMA ($79.54) invalidates the momentum regime and cuts Target Base ($80.16) toward Bear Floor ($60.56).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CBT Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CBT Position Size: $10,000

Shares at $73.85: 135.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $60.56
$8,200
$-1,800 (-18.0%)
12M Consensus BaseTarget $80.16
$10,854
+$854 (+8.5%)
12M Bull Case BreakoutTarget $99.26
$13,441
+$3,441 (+34.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (43 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 32● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$8374%A
Goldman SachsSector Coverage LeadSTRONG BUY$9369%B
JP MorganUS Large-Cap ResearchHOLD$7058%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CBT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.04%📐 HORIZONTAL RANGE
2026-10-30O $73.91H $74.63L $73.50C $73.85VOL 664.0K
RES: $98.90SUP: $71.71SMA50: $77.95SMA200: $79.54
$96.09$89.63$83.17$76.71$70.26RES $98.90SUP $71.71$73.852026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
1.6%/yr Implied 5Y Growth

vs. -7.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CBT)

Materials Rank #4 of 270 ⚔️ AVNT vs CBT Full Matrix →

1. Head-to-Head Materials Peer Comparison (CBT vs. AVNT, VVV, PRM, MEOH)

Industry: Major Chemicals (67 Tracked Issuers)

Across 270 tracked Materials securities in the Roarable RQD universe, Cabot Corporation (CBT) ranks #4 by composite RQD confidence (77/100, grade B+) and #86 by equity capitalization ($3.81B). Within this direct 5-issuer industry benchmark cohort, CBT leads on earnings valuation at 11.5x trailing P/E, while CBT leads on capital efficiency and profitability with 22.3% ROIC and 25.3% gross margin. CBT currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CBT ACTIVE
Cabot Corporation
B+ 77/100 11.5x 25.3% 22.3% +0.11% $3.81B Benchmark Subject
AVNT
Avient Corporation
B- 70/100 48.0x 31.2% 3.7% +1.64% $3.93B /avnt-vs-cbt →
VVV
Valvoline Inc.
D 45/100 19.6x 38.5% 16.5% +1.92% $4.13B /vvv-vs-cbt →
PRM
Perimeter Solutions SA
D 51/100 — 57.5% -10.8% -0.14% $4.67B /prm-vs-cbt →
MEOH
Methanex Corporation
D 51/100 — — — -1.24% $4.86B /meoh-vs-cbt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0000016040

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Cabot Corporation (CBT) reported GAAP revenue of $3.71B (-7.0% vs. FY2024 revenue of $3.99B , and -5.5% cumulative change since FY2023) , GAAP net income of $331.0M, operating cash flow of $665.0M, and free cash flow of $391.0M (-13.3% YoY). On the balance sheet, CBT closed FY2025 with $3.76B in total assets against $854.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $3.71B $331.0M $665.0M $391.0M $3.76B $854.0M
FY2024 (FY) 2024-09-30 $3.99B $380.0M $692.0M $451.0M $3.64B $1.09B
FY2023 (FY) 2023-09-30 $3.93B $445.0M $595.0M $595.0M — —

3. CBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cabot Corporation (NYSE: CBT) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $73.85 (+0.11% 1D, market cap $3.81B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 18/20. Across 270 tracked Materials issuers, CBT ranks #4 in composite RQD confidence.

How does CBT compare to AVNT and VVV in the Materials sector?

Within the Materials sector (Major Chemicals), CBT carries a Roarable B+ (77/100 RQD), trailing P/E of 11.5x, gross margin of 25.3%, and ROIC of 22.3%. By comparison, AVNT (Avient Corporation) holds a B- grade (70/100 RQD, P/E 48.0x, ROIC 3.7%, cap $3.93B) and VVV (Valvoline Inc.) posts a D grade (45/100 RQD, P/E 19.6x, ROIC 16.5%, cap $4.13B). Among the 5-stock peer group, CBT leads on earnings multiple (11.5x) while CBT leads on capital efficiency (22.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CBT?

Per CBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000016040), Cabot Corporation generated $3.71B in revenue (-7.0% YoY), $331.0M in net income, and $391.0M in free cash flow against $3.76B in total assets and $854.0M in total debt. Key quantitative strengths: Strong cash generator (25% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CBT trading relative to its 50-day, 200-day, and 52-week technical levels?

CBT last traded at $73.85 (+0.11% on volume of 392,283 shares), positioning the stock -5.26% below its 50-day simple moving average ($77.95) and -7.15% below its 200-day simple moving average ($79.54). Across its 52-week range of $58.33 to $94.53, CBT sits at the 42.9% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of ±4.5% ($70.53 to $77.17).

CBT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CBT's 12-month stock price target?

Cabot Corporation (CBT) carries a 12-month consensus base price target of $80.16 (+8.5% from $73.85), with a bull-case target of $99.26 and a bear-case floor of $60.56.

Is CBT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CBT B+ (Buy — BUY) with an RQD Confidence score of 77/100.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%